Evaluation of Patients Treated with Natalizumab for Progressive Multifocal LeukoencephalopathyTarek A Yousry, David B. Clifford, Eugene O. Major et al.|New England Journal of Medicine|2006Cited by 792
Induction of a non-encephalitogenic type 2 T helper-cell autoimmune response in multiple sclerosis after administration of an altered peptide ligand in a placebo-controlled, randomized phase II trialLudwig Kappos, Paul D. Crowe, Giancarlo Comi et al.|Nature Medicine|2000Cited by 515
Daclizumab high-yield process in relapsing-remitting multiple sclerosis (SELECT): a randomised, double-blind, placebo-controlled trialRalf Gold, Gilmore O’Neill, Gavin Giovannoni et al.|The Lancet|2013Cited by 287
Standardized MR imaging protocol for multiple sclerosis: Consortium of MS Centers consensus guidelines.Jack H. Simon, Jerry S. Wolinsky, David K.B. Li et al.|PubMed|2006Cited by 287
Magnetic resonance imaging pattern in natalizumab‐associated progressive multifocal leukoencephalopathyTarek Yousry, Massimo Filippi, Daniel Pelletier et al.|Annals of Neurology|2012Cited by 202